Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
CEL-SCI Corp
CVM
Healthcare
Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck...
cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSEAM:CVM)
New Post
View:
Posts & Comments
Threaded Posts
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Sep 16, 2024 9:04am
Great coverage on CVM
https://youtu.be/fAg5VUkO5T0
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 03, 2024 10:51am
CEL-SCI Corporation (CVM): Pioneering Immunotherapy for Head
https://beyondspx.com/2024/08/02/cel-sci-corporation-cvm-pioneering-immunotherapy-for-head-and-neck-cancer-with-promising-phase-3-results/
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Jul 26, 2024 9:19am
BUY BUY BUY BUY BUY
To the moon at 4$and back
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on May 08, 2024 10:15am
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of
JUST IN: $CVM CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerCritical milestone achieved@the FDA accepted CEL-SCI@s selection criteria
...more
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on May 07, 2024 4:04pm
Excellent YT coverage out on CVM
https://youtu.be/YssziKz9Us0?si=pt2yEe4GGZIAd9Oz
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 09, 2024 6:30pm
Why CEL-SCI Corporation (CVM) Shares Are Diving | Benzinga
Breaking News: $CVM Why CEL-SCI Corporation (CVM) Shares Are Diving | BenzingaCEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 13.9% to $2.46 Friday morning after the company priced an
...more
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Jan 30, 2024 5:09pm
Excellent YT analysis on Cel-Sci!
https://youtu.be/i_CYM93Vnb8?si=ZaCOw3Hxek8yvvRe
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >